Objective: To examine the association of blood pressure (BP) with incident Alzheimer's disease (AD) dementia. Methods: This work is based on a longitudinal, cohort study of 18 years, the Chicago Health and Aging Project (CHAP) performed in 2,137 participants (55% black) with systolic BP measured around 8.1 years before incident AD dementia. Results: The association of BP with risk of AD dementia was U-shaped, with the lowest risks of AD dementia near the center of the systolic BP (SBP) and diastolic BP (DBP) distributions, and modestly elevated risk at lower BPs, and greater risk at higher BPs. The degree of U-shape and the range of lowest risk (threshold ranges) varied with antihypertensive medication use and presence of the APOE e4 allele. The U-shape was most prominent for the subgroup not taking antihypertensive medications and having an APOE e4 allele. At higher BPs, those having the APOE e4 allele and not receiving antihypertensive medication were at greater risk of AD dementia than other groups: The risk of incident AD dementia increased by 100% (relative risk [RR] 5 2.00; 95% confidence interval [CI] 5 1.70, 2.31) for every 10 mm Hg increase in SBP above 140 mm Hg. For DBP, the risk of incident of AD dementia increased by 57% (RR 5 1.57; 95% CI 5 1.33, 1.86) for every 5 mm Hg increase in DBP above 76 mm Hg. Interpretation: The BP risk of AD dementia association is U-shaped, with elevated risk at lower and higher BPs. People having the APOE e4 allele and not receiving antihypertensive medication with higher BPs have notably elevated risk of AD dementia. ANN NEUROL 2018;83:935-944 T he association of blood pressure (BP) with risk of Alzheimer's disease (AD dementia) remains unclear despite systematic reviews 1,2 and extensive study, with studies reporting greater risk of AD dementia with higher BP, 3,4 lower risk, 5, 6 and null results in older adults.
T he association of blood pressure (BP) with risk of Alzheimer's disease (AD dementia) remains unclear despite systematic reviews 1, 2 and extensive study, with studies reporting greater risk of AD dementia with higher BP, 3, 4 lower risk, 5, 6 and null results in older adults. 7, 8 The issue is of great public health importance to the aging population because of the high prevalence of hypertension, widespread availability of effective antihypertensive therapy, and paucity of potentially reversible risk factors for AD dementia, and the increasing magnitude of AD dementia as a public health problem with continued rapid growth of the oldest population age groups. 9 
Materials and Methods
The Chicago Health and Aging Project (CHAP), a longitudinal population-based study of AD dementia and other health conditions among adults aged 65 years conducted from 1993 to 2012, enrolled 78.7% of all residents > 65 years from a geographically defined biracial community of blacks and nonHispanic whites. Residents who reached 65 years of age in subsequent years were enrolled in successive age cohorts. Cognitive tests were administered during population interviews conducted in participants' homes in approximately 3-year cycles for up to six cycles over 18 years. Independent detailed clinical evaluations for AD dementia were performed using a stratified random sample of participants at baseline and at 3-year intervals thereafter. 10 At the end of each cycle of population data collection, individuals were selected for a detailed clinical evaluation of incident AD dementia with a probability-based sampling weight. The use of sampling weights ensured that our clinical sample was representative of the population sample from which it was drawn and accounts for missing data attributed to demographic characteristics. A detailed flow chart of individuals selected for clinical evaluation of incident AD dementia is shown in Figure 1 . In essence, 2,137 individuals selected for clinical evaluation of incident AD dementia were cognitively intact during the baseline assessment and eligible to be a part of this investigation. During these clinical evaluations, DNA samples were also extracted and frozen for genotyping at a later date. The Rush University Medical Center Institutional Review Board approved this study. All participants provided signed, written informed consent.
Clinical Diagnosis of AD Dementia
Clinical evaluations were structured and uniform with examiners blinded to population interview cognitive testing and sampling category. 10 It included a structured medical history, neurological examination, and a battery of 19 cognitive function tests. A board-certified neurologist, who was unaware of previously collected data, diagnosed dementia and AD according to the NINCDS-ADRDA criteria. 11 These required a history of cognitive decline and evidence of impairment in two or more cognitive domains, one of which had to be memory. At each in-home interview, use of all medications over the preceding 2-week period was ascertained by direct inspection; medications were then classified using the MediSpan system, which facilitated grouping by biologically active agents, including individual ingredients of combination products, permitting efficient identification of antihypertensive medications. APOE e4 genotypes were ascertained using two single-nucleotide polymorphisms (SNPs): rs7412 and rs429358. These SNPs were genotyped in each subject at the Broad Institute for Population Genetics using the hME Sequenom MassARRAY platform. Genotyping call rates were 100% for SNP rs7412 and 99.8% for SNP rs429358. Both SNPs were in Hardy-Weinberg equilibrium with p values of 0.0833 and 0.7925, respectively. Based on these two SNPs, we created an indicator variable for participants with one or more copies of the APOE e4 allele. Race/ethnicity was measured using the 1990 U.S. Census Question; education was measured as the number of years of formal schooling completed. The presence of heart disease and diabetes was assessed by self-report using questions from the Established Populations for Epidemiologic Study of the Elderly.
Statistical Analysis
Descriptive analyses were stratified by antihypertensive medication use and the presence of the APOEe4 allele, and presented using means and SDs for continuous measures, and frequencies and percentages for categorical measures. Baseline characteristics were compared using a two-sample t test and a chi-squared test statistic depending on the type of measure. A Cox proportional hazards model was used to estimate the relative risk of AD dementia using time from baseline to clinical diagnosis of AD dementia, and a censoring variable denoting the end of observation or clinical diagnosis of AD dementia. All models were adjusted for age (centered at 75), sex (male versus females), race (blacks versus non-blacks), education (centered at 12), and an indicator for BP measurement instrument. In a sensitivity analysis, we included additional confounders, such as baseline measures of body mass index <18.5, 18.5 to 24.9, 25.0 to 29.9, and 301, overall dietary quality, current and past smoking status, grams of alcohol and caffeine intake, and hours of physical activity, and number of depressive symptoms to examine whether the association of systolic BPP (SBP) and diastolic BP (DBP) with incident AD in APOE and BP medication groups were independent of the confounders. A visual inspection of the probability of incidence AD dementia against the levels of SBP and DBP was performed to assess the degree of association nonparametrically before any regression analysis. The number of individuals with incident AD dementia divided by the number of individuals in every 10 mm Hg interval was plotted against the midpoint of the interval. Based on these nonparametric plots, we visually inspected the degree of association before our regression-based approach.
For regression models, first, a linear risk function was used to examine the associations of SBP and DBP with the risk of developing AD dementia. Second, a smoothed penalized quadratic spline of an evenly spaced basis function for BP was used to examine the change in log hazard function over the range of SBP. 13 The regression terms for the spline basis function of BP was used to examine the minimum of the log hazard function over the values of BP to estimate the threshold-like value. A model-based resampling algorithm for right-censored data was used to estimate the confidence intervals (CIs) around the minimum value of the log hazard function. Given that the tails of the risk function, at high values of SBP and DBP, could be influenced by extreme observations, and given that only a small fraction, generally less than 3%, had such high and low BPs, we truncated low and high SBPs at 100 and 220 mm Hg, respectively; this range was set at 50 to 110 mm Hg for DBP. A quadratic spline model had higher log pseudo-likelihood values than a linear model in most of our models. A sensitivity analysis for the quadratic spline model was performed by fitting a cubic spline with two unknown knots, which did not improve our model fit. We used a bootstrap resampling technique to account for fitting of the hazard model and selection of the minimum log hazard ratio to obtain point estimates and CIs of the log hazard ratios for our sampling weight-based selection process. The single knot of the quadratic spline model, where the risk function changes direction, was termed as an optimal value, and CIs for these optimal values were also estimated using bootstrap approach. Bootstrap-based point-wise standard errors were used to estimate CIs around the hazard curves and to test optimal values and hazard ratios between APOE and BP groups. The analysis was stratified by the use of antihypertensive medication and the presence of the APOEe4 allele, and performed using coxph, pspline, and censboot functions in the R program.
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Results
In a stratified random sample of 2,137 community residents aged > 65 years who underwent clinical evaluation for AD dementia (Table 1) , the average age was 73.1 years with average education 13.0 years, mostly women (63%) and a higher fraction of blacks (55%). Approximately 11% also reported heart disease and 6% reported diabetes. Average BPs were 138.5 mm Hg (SBP) and 77.2 mm Hg (DBP), with 57% using one or more antihypertensive medication and 31% had at least one APOEe4 allele, and 437 (20%) had developed AD dementia at clinical evaluation. Participants using antihypertensive medication reported having a higher SBP, education, and self-report of heart disease or diabetes, but not having an APOEe4 allele. No significant difference in SBP (p 5 0.24) and DBP (p 5 0.55) was found between participants with and without the APOEe4 allele.
In general, our overall analysis found the association of systolic and diastolic BP with the risk of incident AD dementia to be U-shaped and asymmetric (Fig 2) . The lowest risk of AD dementia was near the center of the SBP and DBP distributions, with lower BP associated with modestly elevated risk of incident AD dementia and higher BPs with greater elevation of risk.
Modification by the APOEe4 Allele For subjects having the APOE e4 allele, the risk of incident AD dementia appeared to be more elevated at both low and high BPs than for those without this allele for both SBP and DBP (Fig 3) . For people with one or more copies of the APOEe4 allele (Table 2) (Table 2) , the association did not show a U-shape especially for DBP, for which it was linear with slightly lower risk of AD dementia at higher DBP (not significant quadratic term, p 5 0.58). For people with higher SBP and without the APOE e4 allele, the RR increased by 13% (RR 5 1.13; 95% CI 5 1.05, 1.21) for every 10 mm Hg increase in SBP above 143 mm Hg, which was significantly lower than the RR for those with the APOE e4 allele (95% CI of log RR difference 5 0.13, 0.35; p < 0.001). For those with lower SBPs and no APOEe4 allele, the risk of incident AD dementia decreased by 12% (RR 5 0.88; 95% CI 5 0.80, 0.96) for every 10 mm Hg increase in SBP below 143 mm Hg, which was significantly different from those with the APOEe4 allele (95% CI of log RR difference 5 0.11, 0.34; p < 0.001). For DBP, a zone of threshold risk of AD dementia could not be calculated, because the association appeared to be roughly linear (not significant quadratic term, p 5 0.67).
Modification by Use of Antihypertensive Medication
Comparing users of antihypertensive medication to nonusers, the U-shaped association appeared most prominent for SBP among nonusers of antihypertensive medication (Fig 3) . For both SBP and DBP among users and for DBP among medication users, lower BPs were associated with modestly elevated risk of incident AD dementia and higher BPs with greater elevation of risk. For medication users, the risk of incident AD dementia increased by 9% (RR 5 1.09; 95% CI 5 1.04, 1.15) for every 10 mm Hg increase in SBP above 120 mm Hg and by 18% (RR 5 1.30; 95% CI 5 1.17, 1.44) for every 5 mm Hg increase in DBP above 76 mm Hg. Below the threshold range, the RR of incident AD dementia was not significantly associated with SBP or DBP. Among medication nonusers (Table 2) , the risk of incident AD dementia increased by 30% (RR 5 1.30; 95% CI 5 1.17, 1.44) for every 10 mm Hg increase in SBP above 150 mm Hg, which was significantly higher than those taking BP medications (95% CI of log RR difference 5 0.08, 0.27; p < 0.001). For DBP among nonusers, however, the association with risk of incident AD dementia was roughly linear with higher risk at lower DBPs; a zone of threshold risk of incident AD dementia was elevated on lower ends and flat on higher ends, the risk of incident AD dementia decreased by 10% (RR 5 0.90; 95% CI 5 0.84, 0.96) for every 5 mm Hg increase in DBP below 84 mm Hg, and no observable elevated risk above the threshold. Participants taking BP medications had similar risk of incident AD dementia below the DBP threshold (95% CI of log RR difference 5 20.13, 0.18; p 5 0.75) and above the DBP threshold (95% CI of log RR difference 5 20.04, 0.31; p 5 0.128) compared to those not taking BP medications.
Interaction of Use of Antihypertensive Medication and Presence of the APOEe4 Allele
In analyses considering use of antihypertensive medication and presence of the APOEe4 allele jointly, the risk of AD dementia was most substantially elevated among those having the APOE e4 allele and not receiving any antihypertensive medication at higher BP levels. The SBP-AD dementia association was markedly U-shaped in this subgroup (Fig 4) . Above the threshold (Table 2) , the risk of incident AD dementia increased by 2-fold for every 10 mm Hg increase in systolic BP over 139 mm Hg (RR 5 2.00; 95% CI 5 1.70, 2.31). Below the threshold, the risk of incident AD dementia decreased by 44% (RR 5 0.56; 95% CI 5 0.46, 0.68) for every 10 mm Hg increase in systolic BP below 139 mm Hg. For DBP, the U-shape of the association was asymmetric with markedly higher risk of incident at higher DBP levels (Fig 4) . Above 76 mm Hg DBP, the risk of incident AD dementia was strongly elevated ( Table 2 ): The risk of incident AD increased by 57% (RR 5 1.57; 95% CI 5 1.33, 1.86) for every 10 mmHg increase in DBP. Below the threshold, the risk of incident AD dementia decreased by 40% (RR 5 0.60; 95% CI 5 0.51, 0.72) for every 5 mm Hg increase in DBP. In the subgroup having Estimates adjusted for age, education, race, sex, heart disease, and diabetes. The presence of APOE e4 allele adjusted for medication use, and medication use adjusted for APOE e4 allele estimates. a No observable change in pattern of log hazard function suggests the use of linear risk estimates.
AD 5 Alzheimer's disease; BP 5 blood pressure; SBP 5 systolic blood pressure; DBP 5 diastolic blood pressure; CI 5 confidence interval.
the APOE e4 allele and receiving antihypertensive medication, the SBP-AD dementia association was modestly U-shaped (Fig 4) . Above 141 mm Hg SBP (Table 2) , the risk of increased AD dementia increased by 17% (RR 5 1.17; 95% CI 5 1.02, 1.35) for every 10 mm Hg increase in SBP, which was significantly lower than the increase in risk for those with the APOEe4 allele above the threshold (95% CI of log RR difference 5 20.69, -0.38; p < 0.001). Below the threshold, the risk of incident AD dementia decreased by 19% (RR 5 0.81; 95% CI 5 0.67, 0.97) for every 10 mm Hg increase in SBP, and significantly different from the risk below the threshold among those with the the APOEe4 allele (95% CI of log RR difference 5 0.20, 0.53; p < 0.001). A similar U-shaped association was observed for DBP. Among those not having the APOE e4 allele and not receiving antihypertensive medication, the SBP-AD dementia association was moderately U-shaped (Fig 4) . Above 153 mmHg SBP, the risk of incident AD dementia increased by 29% (RR 5 1.29; 95% CI 5 1.08, 1.54) for every 10 mm Hg increase in SBP. Below the threshold, the risk of incident AD dementia decreased by 23% (RR 5 0.77; 95% CI 5 0.69, 0.86) for every 10 mm Hg increase in SBP. In the subgroup not having the APOE e4 allele and receiving antihypertensive medication, the form of the SBP-AD dementia association differed from that observed for the three other subgroups, with little or no U-shape (Fig 4) , and the highest risk at the highest SBPs and an optimal SBP region could not be calculated. For DBP, among those not having the APOE e4 allele and not receiving antihypertensive medication, the association with risk of incident AD dementia was roughly linear with higher risk at lower DBP levels, and an optimal DBP region could not be calculated. Among those not having the APOE e4 allele and receiving antihypertensive medication, the form of the association was curvilinear with a linear increase in the risk of incident AD dementia by 9% (RR 5 1.09; 95% CI 5 1.02, 1.16) for every 5 mm Hg increase in DBP, with no clear indication of the presence of a threshold DBP (not significant quadratic term, p 5 0.73). Among participants with no APOEe4 allele, a significant difference in relative risk was found for those taking BP medications compared to those not taking BP medications (95% CI of log RR difference 5 0.06, 0.27; p 5 0.004).
Sensitivity Analysis
The inclusion of health and lifestyle measures did not change the BP thresholds, but most notably, the risk of incident AD dementia among those not taking BP medications and without the APOE e4 allele was from 29% (RR 5 1.29; 95% CI 5 1.08, 1.54) to 34% (RR 5 1.34; 95% CI 5 1.13, 1.58) for every 10 mm Hg increase in SBP over 153 mm Hg. Health and lifestyle did not change the thresholds or risk estimates in other groups of the APOE e4 allele and BP medication combinations. In an additional sensitivity analysis, we excluded individuals with APOE e2/e2, e2/e3, and e2/e4 from our analytical sample, and found that the BP thresholds and risk estimates did not show any notable differences. This may be attributed to the small number of individuals with the APOE e2 alleles.
Discussion
Our results suggest that the association between BP and risk of developing AD dementia is U-shaped, with lowest risk of AD dementia near the center of the BP distribution. Lower BP was associated with modestly elevated risk of incident AD dementia and high BPs with higher risk. This association varied strongly with medication use and presence of the APOE e4 allele. At higher BPs, those having the APOE e4 allele and not receiving antihypertensive medication were at greatly elevated risk of AD dementia.
Most epidemiological studies of a BP-AD dementia association have used linear analytical techniques and focused on increased risk of AD dementia with higher BP. The large variation in results (reviewed in a previous work 2 ) may be partially attributable to the U-shaped association. Some studies, however, have suggested that there may be elevated risk of AD dementia at both ends of the BP spectrum. Longitudinal results 14 18 Pandav et al reported an inverse cross-sectional association of cognitive impairment with higher SBP in the Indian arm of a cross-national study and a similar borderline association in the US arm.
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A few previous reports have also suggested that BP, the APOEe4 allele, and use of antihypertensive medication may interact: Peila et al found a higher risk of poor late-life cognitive function for people having the APOEe4 allele and higher midlife SBP. 20 In contrast, Qiu et al found a higher risk of AD dementia for people having the APOEe4 allele and lower DBP who were also antihypertensive medication users. 21 Studies [22] [23] [24] [25] [26] have also suggested that the presence of the APOEe4 allele modifies the association of other vascular conditions with cognitive decline, although findings have not been uniform. 27, 28 The mechanisms underlying the form of the observed associations are uncertain. Arguments have been made that U-shaped biological and pharmacological associations are a general phenomenon and an example of biological optimization. 29 Among older people, some risk factor/disease associations seem either paradoxical in direction compared to those typically observed in middle age or demonstrate a U-shaped pattern. 30 The U-shaped form of the BP-incident AD dementia association is generally consistent with this pattern, but insights as to the specific mechanisms involved are limited. Because of limited sample size and the type of modeling approach, formal comparisons of risk curves, notably the optimum thresholds and relative risk estimates, were not performed, even when a CI was estimated. Another limitation is that the variability around the hazard ratio curves were not estimated, because a bootstrap approach was used to estimate the variability around thresholds and variability in RRs above and below the thresholds. A single class of medications with antihypertensive properties was considered, but the protective associations may vary by specific types of antihypertensive medications, which need to be further evaluated in future work. Strengths of the study include its size, populationbased biracial design, and long duration between BP measurements and clinical diagnosis of incident AD dementia. Limitations include the lack of plainly evident mechanisms underlying each of its four major findings: the U-shaped BP-AD dementia association; modification of this association by presence of the APOEe4 allele and antihypertensive medication use; and interaction of the APOEe4 and antihypertensive medication associations. Nonetheless, the observation of all four major findings with both SBP and DBP, consistency with some aspects of previous findings, and ability to partially explain the great variation in results of previous studies of the BP-AD dementia association argue for careful consideration pending confirmation or refutation by future investigations. The strong risk of incident AD dementia observed with higher SBP and DBP among people having the APOE e4 allele and not taking antihypertensive medication seems highly relevant to clinical care of this group, given that use of antihypertensive agents in those with the APOE e4 allele seems to have lower increases in relative risk of incident AD dementia.
